GLP-1 Agonist and Respiratory System Complications: A Comprehensive Review
The use of glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the management of type 2 diabetes and obesity. However, recent studies have highlighted the potential respiratory system complications associated with the use of these medications. In this article, we will provide a comprehensive review of the GLP-1 agonist and respiratory system complications, including the benefits and risks of these medications.
Background
GLP-1 receptor agonists are a class of injectable medications that improve glycemic control and weight loss in patients with type 2 diabetes. These medications work by slowing gastric emptying, reducing appetite, and increasing feelings of fullness. However, the use of these medications has been associated with various side effects, including respiratory system complications.
Respiratory System Complications
Studies have shown that GLP-1 receptor agonists may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections. A systematic review of 14 clinical trials found that GLP-1 receptor agonists reduced the risk of respiratory diseases by 14-26% in high-risk patients. Another study found that semaglutide, liraglutide, and dulaglutide reduced the risk of respiratory diseases by 18%, 14%, and 18%, respectively.
Benefits of GLP-1 Agonists
GLP-1 receptor agonists have been shown to provide lung benefits beyond glycemic control, including reduced risks of lung malignancy, pulmonary infection, and chronic obstructive pulmonary disease (COPD) exacerbations. A study found that patients taking GLP-1 receptor agonists had a reduced risk of COPD exacerbations and hospitalizations.
